Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Cash & Current Investments (2021 - 2025)

Core Scientific's Cash & Current Investments history spans 5 years, with the latest figure at $453.4 million for Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 78.64% year-over-year to $453.4 million; the TTM value through Sep 2025 reached $453.4 million, up 78.64%, while the annual FY2024 figure was $837.0 million, 1100.68% up from the prior year.
  • Cash & Current Investments for Q3 2025 was $453.4 million at Core Scientific, down from $581.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $837.0 million in Q4 2024 and bottomed at $1.6 million in Q3 2021.
  • The 5-year median for Cash & Current Investments is $110.4 million (2022), against an average of $204.4 million.
  • The largest YoY upside for Cash & Current Investments was 7856.05% in 2022 against a maximum downside of 60.33% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $131.7 million in 2021, then tumbled by 60.33% to $52.2 million in 2022, then skyrocketed by 33.44% to $69.7 million in 2023, then soared by 1100.68% to $837.0 million in 2024, then tumbled by 45.83% to $453.4 million in 2025.
  • Per Business Quant, the three most recent readings for CORZ's Cash & Current Investments are $453.4 million (Q3 2025), $581.3 million (Q2 2025), and $698.7 million (Q1 2025).